Genmab — December 2025
-
-
#ASH25 | PRESENTATION
Philip Thompson,
@MDAndersonNews@PeterMacCC
, presents first results of epcoritamab + lenalidomide (Arm 2B; N = 11) and epcoritamab + R-CHOP (Arm 2C; N = 30) in patients with Richter transformation from the phase Ib/II EPCORE CLL-1 trial. https://x.com/lymphomahub/status/1998150848279609470 -
ASH: J&J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma https://www.fiercepharma.com/pharma/jj-makes-case-tecvayli-combo-alternative-car-t-second-line-multiple-myeloma
-
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI
plus DARZALEX FASPRO as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma https://www.prnewswire.com/news-releases/unprecedented-results-from-the-phase-3-majestec-3-study-support-tecvayli-plus-darzalex-faspro-as-a-potential-standard-of-care-as-early-as-second-line-for-patients-with-relapsedrefractory-multiple-myeloma-302636559.html?tc=eml_cleartime -
NEJM -
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma https://www.nejm.org/doi/full/10.1056/NEJMoa2514663 -
"The Company has submitted a supplemental Biologics License Application (sBLA) for the use of TECVAYLI
and DARZALEX FASPRO in combination as a treatment for RRMM to the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy Designation (BTD) for the combination regimen" -
Raun..I en teknisk uptrend vil der altid være tilbagefald og sidelæns bevægelse. Det kan ske i kortere og længere tid. I de seneste 6 måneder har aktien steget med 40%. Helt naturlig at der pustes ud på de toppe som sættes undervejs.
-
RAINFOL-03 starts Recruiting https://clinicaltrials.gov/study/NCT07166094?tab=history&a=6&b=7#version-content-panel -Endometrial Cancer
-
Vil virkelig gerne være enig med dig Helge..... Men det jeg har set igennem de sidste måneder er ikke en normal optrend - det er en styring.... Det er en sidelæns bevægelse i 2 skridt frem og 2 skridt tilbage og sådan har det været konstant efter aktien satte sig efter købet af Merus..... Og som sædvanlig har vi haft pæne og gode nyheder, som skulle styrke optrenden, men som sædvanlig udebliver det positive afkast
-
Ja, men det ser umiddelbart ud som gammelt nyt https://cslide.ctimeetingtech.com/coasis_21467/attendee/confcal_1/presentation/list?q=Acasunlimab
-
Merus shareholders voted to approve the acquisition by Genmab https://ir.merus.nl/static-files/b12d72b3-80f6-4b63-81b2-4177c911cfb4 https://ir.merus.nl/static-files/68e405c1-7aa2-4a88-9282-31ec5f5d5aa2
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind